Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07587515

Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Neovascular (Wet) Age-related Macular Degeneration Eye Diseases Macular Degeneration Retinal Degeneration Retinal Diseases

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Beverly Hills, CA, Beverly Hills, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria
  • Willing and able to comply with clinic visits and study-related procedures
  • Provide signed informed consent

Exclusion criteria

  • Known hypersensitivity or known allergy that would preclude study drug administration
  • Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access
  • Uncontrolled diabetes mellitus
  • History of cerebrovascular accident (CVA) or myocardial infarction within 180 days of the Day 1 visit
  • Renal failure, dialysis, or history of renal transplant
  • Concurrent psychiatric or medical condition that in the opinion of the Investigator will interfere with study participation or completion
  • Pregnant or breastfeeding women

Treatment and study plan

EYC-0305

Biological

Extended-delivery anti-VEGF

Primary outcomes

  1. Incidence and severity of ocular treatment-emergent adverse events (TEAEs)

    Time frame: Week 72

  2. Incidence and severity of systemic treatment-emergent adverse events (TEAEs)

    Time frame: Week 72

Study contacts

Contact information is provided by the study sponsor or research team.

Karen Chu, MS

CONTACT

[email protected]

1-866-392-6647

Kim Reed, OD, FAAO

CONTACT

[email protected]

1-866-392-6647

Sponsors and collaborators

Lead sponsor

Eyconis INC.

Other

Registry information

Official study title

Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration

Acronym: OVERTURE

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
May 14, 2026
Registry last updated
Jul 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.